Jonathan Shuter1, Alyson B Moadel2, Ryung S Kim2, Andrea H Weinberger3, Cassandra A Stanton4. 1. AIDS Center and Division of Infectious Diseases, Montefiore Medical Center, and Albert Einstein College of Medicine, Bronx, NY; jshuter@montefiore.org. 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY; 3. Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Cancer Prevention and Control Research Program, Yale Cancer Center, New Haven, CT; 4. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
Abstract
INTRODUCTION: Tobacco use is epidemic among persons living with HIV (PLWH), and several studies have shown self-efficacy (SE) to be a predictor of successful cessation. This study examined sociobehavioral correlates of SE and its predictive value for successful cessation in a group of PLWH smokers. METHODS: The study was conducted on combined patient data from 2 separate randomized controlled trials of tobacco treatment for PLWH smokers. Both trials utilized the same SE scale at the same timepoints, and both had the same smoking cessation endpoint (biochemically confirmed, 7-day, point prevalence abstinence at 3 months). Univariate and multivariate techniques were used to analyze the merged dataset. RESULTS: Baseline SE data were available for 272 subjects. The Self-Efficacy/Temptations Scale-Long Form demonstrated good internal reliability with overall and subscale Cronbach's alpha of .77-.92. Younger age, HIV risk other than injection drug use, recent alcohol use, and higher scores for anxiety, depression, loneliness, and nicotine dependence were all significantly correlated with lower baseline SE. Posttreatment SE was significantly predictive of successful cessation, whereas baseline SE was not. Subjects randomized to the treatment interventions were significantly more likely to quit (AOR = 2.99 [1.26-7.01], p = .01), and logistic regression suggested a possible mediating effect of posttreatment SE. CONCLUSIONS: SE is tightly correlated with a number of modifiable affective and behavioral factors in PLWH smokers, and measures aimed at increasing the SE to abstain in such individuals may enhance the effect of targeted tobacco treatment strategies.
RCT Entities:
INTRODUCTION:Tobacco use is epidemic among persons living with HIV (PLWH), and several studies have shown self-efficacy (SE) to be a predictor of successful cessation. This study examined sociobehavioral correlates of SE and its predictive value for successful cessation in a group of PLWH smokers. METHODS: The study was conducted on combined patient data from 2 separate randomized controlled trials of tobacco treatment for PLWH smokers. Both trials utilized the same SE scale at the same timepoints, and both had the same smoking cessation endpoint (biochemically confirmed, 7-day, point prevalence abstinence at 3 months). Univariate and multivariate techniques were used to analyze the merged dataset. RESULTS: Baseline SE data were available for 272 subjects. The Self-Efficacy/Temptations Scale-Long Form demonstrated good internal reliability with overall and subscale Cronbach's alpha of .77-.92. Younger age, HIV risk other than injection drug use, recent alcohol use, and higher scores for anxiety, depression, loneliness, and nicotine dependence were all significantly correlated with lower baseline SE. Posttreatment SE was significantly predictive of successful cessation, whereas baseline SE was not. Subjects randomized to the treatment interventions were significantly more likely to quit (AOR = 2.99 [1.26-7.01], p = .01), and logistic regression suggested a possible mediating effect of posttreatment SE. CONCLUSIONS: SE is tightly correlated with a number of modifiable affective and behavioral factors in PLWH smokers, and measures aimed at increasing the SE to abstain in such individuals may enhance the effect of targeted tobacco treatment strategies.
Authors: Chad J Gwaltney; Saul Shiffman; Jean A Paty; Ken S Liu; Jon D Kassel; Maryann Gnys; Mary Hickcox Journal: J Consult Clin Psychol Date: 2002-10
Authors: Jonathan Shuter; Daniela A Morales; Shannon E Considine-Dunn; Lawrence C An; Cassandra A Stanton Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Cassandra A Stanton; Elizabeth E Lloyd-Richardson; George D Papandonatos; Marcel A de Dios; Raymond Niaura Journal: AIDS Educ Prev Date: 2009-06
Authors: Andrea H Weinberger; Philip H Smith; Allison P Funk; Shayna Rabin; Jonathan Shuter Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Damon J Vidrine; George Kypriotakis; Liang Li; Roberto C Arduino; Faith E Fletcher; Irene Tamí-Maury; Ellen R Gritz Journal: Drug Alcohol Depend Date: 2014-12-15 Impact factor: 4.492
Authors: Noreen Dadirai Mdege; Fredrick Edward Makumbi; Ronald Ssenyonga; Frances Thirlway; Joseph K B Matovu; Elena Ratschen; Kamran Siddiqi; Kellen Nyamurungi Namusisi Journal: Nicotine Tob Res Date: 2021-06-08 Impact factor: 4.244